IsoPlexis Stock

isoplexis.comHealthcare / BioTech & PharmaFounded: 2013Funding to Date: $161.52MM

IsoPlexis is building solutions to accelerate the development of curative medicines and personalized therapeutics.

Register To Buy and Sell Shares

For more details on financing and valuation for IsoPlexis, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access IsoPlexis’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like IsoPlexis.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.

News Highlights

IsoPlexis Preliminary Q1 Revenues Rise up to 52 Percent; Firm Cuts 20 Percent of Workforce
The newly public provider of single-cell analysis technologies said that the reorganization would help extend its cash runway into the second half of 2024.
People in the News: New Appointments at NeoGenomics, Mainz Biomed, IsoPlexis, More
IsoPlexis Using IPO Funds to Support Move Into Transcriptomics, Metabolomics
The firm is expanding beyond single-cell proteomics with new data types that could help it move into research areas outside its traditional immune profiling focus.
Updated on: Apr 15, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.